LFB is a pharmaceutical group specialising in plasma derived or recombinant therapeutic proteins for the treatment of serious and often rare diseases.
Since the creation of LFB in January 1994, discover the dates that gone down the Group's history.
Worldwide, LFB has decided on a targeted strategy
LFB has a special place in France, as a player in the healthcare industry with a public health mission
A public company active in a competitive market
Discover a series of three videos looking back at the company's transformation over the last few years and unveiling its future objectives.
15 hospital-prescribed medicinal products
LFB confirms its commitment to research for the benefit of patients by launching the second edition, "LFB Research Grant in Immunology."
Patient safety, a top priority for LFB
There are several medicinal products at an advanced stage of development, for registration in Europe and the USA
Two proprietary platforms for therapeutic and technological innovation
Innovations to constantly improve the biosafety of medicinal products
LFB has a continuing commitment to social issues, offering several therapeutic solutions, both currently on sale and under development, for rare diseases
LFB is a partner in several patients’ associations and supports projects focused on a better quality of life for patients and their families
LFB’s ethical commitment is reflected in the way it exercises its environmental, social and economic responsibilities
Transparency of interests for France
Home › Pushs › Agreement with Xenothera to manufacture a treatment for CORONAVIRUS INFECTIONS INCLUDING COVID-19